Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
David W. Hein & Lori M. Millner. (2021) Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review. Expert Opinion on Drug Metabolism & Toxicology 17:1, pages 9-21.
Read now
Read now
Jayaprakasam Bolleddula, Kevin DeMent, James P. Driscoll, Philip Worboys, Patrick J. Brassil & David L. Bourdet. (2014) Biotransformation and bioactivation reactions of alicyclic amines in drug molecules. Drug Metabolism Reviews 46:3, pages 379-419.
Read now
Read now
Meenu Jain, Shaleen Kumar, Puneeta Lal, Anu Tiwari, U. C. Ghoshal & Balraj Mittal. (2007) Association of Genetic Polymorphisms of N-Acetyltransferase 2 and Susceptibility to Esophageal Cancer in North Indian Population. Cancer Investigation 25:5, pages 340-346.
Read now
Read now
Articles from other publishers (55)
Sadaf Saleem, Imtiaz Mahmood Tahir, Tahira Iqbal, Amer Jamil, Huma Mehboob, Muhammad Akram & Peter Olusakin Oladoye. (2021) Genetic polymorphism of NAT1 in local Pakistani population. Gene Reports 25, pages 101343.
Crossref
Crossref
Jeong Yee, So Min Kim, Ji Min Han, Nari Lee, Ha Young Yoon & Hye Sun Gwak. (2020) The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Scientific Reports 10:1.
Crossref
Crossref
Kimberly S. Collins, Anthony L.J. Raviele, Amanda L. Elchynski, Alexander M. Woodcock, Yang Zhao, Rhonda M. Cooper-DeHoff & Michael T. Eadon. (2020) Genotype-Guided Hydralazine Therapy. American Journal of Nephrology 51:10, pages 764-776.
Crossref
Crossref
David W. Hein, Giannoulis Fakis & Sotiria Boukouvala. (2018) Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles. Pharmacogenetics and Genomics 28:10, pages 238-244.
Crossref
Crossref
Ines Potočnjak, Robert Likić, Iveta Šimić, Danica Juričić Nahal, Ivana Čegec, Lana Ganoci & Nada Božina. (2017)
Dapsone-induced agranulocytosis-possible involvement of low-activity
N
-acetyltransferase 2
. Fundamental & Clinical Pharmacology 31:5, pages 580-586.
Crossref
Crossref
J Matthaei, MV Tzvetkov, J Strube, D Sehrt, C Sachse-Seeboth, JB Hjelmborg, S Möller, U Halekoh, U Hofmann, M Schwab, R Kerb & J Brockmöller. (2016) Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2. Clinical Pharmacology & Therapeutics 100:6, pages 606-616.
Crossref
Crossref
J. Detert & G. R. Burmester. (2016) „Treat to target“ und personalisierte Medizin („precision medicine“)Treat to target and personalized medicine (precision medicine). Zeitschrift für Rheumatologie 75:6, pages 624-632.
Crossref
Crossref
Yanjie Hu, Suting Chen, Xia Yu, Guangming Dai, Lingling Dong, Yunxu Li, Liping Zhao & Hairong Huang. (2016)
Rapid identification of the
NAT2
genotype in tuberculosis patients by multicolor melting curve analysis
. Pharmacogenomics 17:11, pages 1211-1218.
Crossref
Crossref
D. M. Lukyanova, T. Yu. Smolnova & L. V. Adamyan. (2016) Modern molecular genetic and biochemical predictors of genital prolapse (a review). Problemy reproduktsii 22:4, pages 8.
Crossref
Crossref
Azza M. Kamel, Gamal T. A. Ebid & Heba S. Moussa. (2015) N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia. Tumor Biology 36:8, pages 6341-6348.
Crossref
Crossref
Loredana Serpe, Roberto Canaparo, Maria Gabriella Scordo & Edoardo Spina. (2015) Pharmacogenetics of drug-metabolizing enzymes in Italian populations. Drug Metabolism and Personalized Therapy 30:2, pages 107-120.
Crossref
Crossref
R. Salazar-González, R. Gómez, S. Romano-Moreno, S. Medellín-Garibay, A. Núñez-Ruíz, M. Magaña-Aquino, R. C. Milán-Segovia & D. P. Portales-Pérez. (2014) Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population. Molecular Biology Reports 41:12, pages 7833-7843.
Crossref
Crossref
Ellen M. McDonagh, Sotiria Boukouvala, Eleni Aklillu, David W. Hein, Russ B. Altman & Teri E. Klein. (2014) PharmGKB summary. Pharmacogenetics and Genomics 24:8, pages 409-425.
Crossref
Crossref
Petra Seibold, Alina Vrieling, Judith Heinz, Nadia Obi, Hans-Peter Sinn, Dieter Flesch-Janys & Jenny Chang-Claude. (2014) Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – Differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. Cancer Epidemiology 38:4, pages 419-426.
Crossref
Crossref
Julia Stingl (formerly Kirchheiner)Jürgen Brockmöller. 2013. Pharmacogenomics. Pharmacogenomics
309
341
.
Anne M.J. Gilsing, Sonja I Berndt, Elizabeth
H Ruder, Barry I Graubard, Leah M Ferrucci, Laura Burdett, Joel L. Weissfeld, Amanda J Cross & Rashmi Sinha. (2012) Meat-related mutagen exposure, xenobiotic metabolizing gene polymorphisms and the risk of advanced colorectal adenoma and cancer. Carcinogenesis 33:7, pages 1332-1339.
Crossref
Crossref
Ingolf Cascorbi. 2012. Pharmacogenetics and Individualized Therapy. Pharmacogenetics and Individualized Therapy
81
100
.
David W Hein & Mark A Doll. (2012)
Accuracy of various human
NAT2
SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes
. Pharmacogenomics 13:1, pages 31-41.
Crossref
Crossref
Aminata Touré, Mathilde Cabral, Cheikh Diop, Nar Diéne, Mamadou Fall, Amadou Moctar Diéye, Amadou Diouf, Michel Lhermitte & Luc Humbert. (2012) Détermination du polymorphisme d’acétylation de la N-acétyltransférase 2 dans la population sénégalaise par utilisation du test à la caféine. Annales de Toxicologie Analytique 24:3, pages 119-127.
Crossref
Crossref
Takuya Terai, Kazuya Kikuchi, Yasuteru Urano, Hirotatsu Kojima & Tetsuo Nagano. (2012) A long-lived luminescent probe to sensitively detect arylamine N-acetyltransferase (NAT) activity of cells. Chemical Communications 48:16, pages 2234.
Crossref
Crossref
Mike UferRobert Häsler, Gunnar Jacobs, Sierk HaenischSandra LächeltFrank FaltracoChristian Sina, Philip Rosenstiel, Susanna Nikolaus, Stefan Schreiber & Ingolf Cascorbi. (2009) Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. Pharmacogenomics 10:12, pages 1941-1953.
Crossref
Crossref
Evgeny Krynetskiy & Ina Lee Calligaro. (2009) Introducing Pharmacy Students to Pharmacogenomic Analysis. American Journal of Pharmaceutical Education 73:4, pages 71.
Crossref
Crossref
Margareta Littorin, Saimei Hou, Karin Broberg, Jonas Björk, Susanne Fält, Galbani Abdoulaye, Malgorzata Kalemba, Charlotta Ryk & Staffan Skerfving. (2007) Influence of polymorphic metabolic enzymes on biotransformation and effects of diphenylmethane diisocyanate. International Archives of Occupational and Environmental Health 81:4, pages 429-441.
Crossref
Crossref
Christine B. Ambrosone, Silke Kropp, Jun Yang, Song Yao, Peter G. Shields & Jenny Chang-Claude. (2008)
Cigarette Smoking,
N-Acetyltransferase 2
Genotypes, and Breast Cancer Risk: Pooled Analysis and Meta-analysis
. Cancer Epidemiology, Biomarkers & Prevention 17:1, pages 15-26.
Crossref
Crossref
Ivar Roots, Gabriele Laschinski & Urs A. Meyer. 2008. Grundlagen der Molekularen Medizin. Grundlagen der Molekularen Medizin
314
331
.
K. Dilger, D. Trenk, M. Rössle, M. Cap, A. Zähringer, V. Wacheck, C. Remmler, I. Cascorbi, W. Kreisel & G. Novacek. (2007) A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. European Journal of Clinical Investigation 37:7, pages 558-565.
Crossref
Crossref
Michael R. Franklin. 2007. xPharm: The Comprehensive Pharmacology Reference. xPharm: The Comprehensive Pharmacology Reference
1
5
.
Georgia Salanti, Julian P. T. Higgins & Ian R. White. (2006) Bayesian synthesis of epidemiological evidence with different combinations of exposure groups: application to a gene–gene–environment interaction. Statistics in Medicine 25:24, pages 4147-4163.
Crossref
Crossref
I. V. Goldenkova-Pavlova, S. A. Brouskin, R. M. Abdeev, E. V. Markarova, S. G. Bigvava, L. A. Radkevich, H. A. Kurdanov, Zh. M. Kozhekbaeva, A. S. Glotov, O. A. Gra, A. S. Zasedatelev, T. V. Nasedkina & E. S. Piruzyan. (2006) Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping. Russian Journal of Genetics 42:8, pages 947-953.
Crossref
Crossref
D W Hein. (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25:11, pages 1649-1658.
Crossref
Crossref
Esther F.A. Brandon, Tessa M. Bosch, Maarten J. Deenen, Rianne Levink, Everdina van der Wal, Joyce B.M. van Meerveld, Monique Bijl, Jos H. Beijnen, Jan H.M. Schellens & Irma Meijerman. (2006) Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines. Toxicology and Applied Pharmacology 211:1, pages 1-10.
Crossref
Crossref
Carmen Lilla, Emaculate Verla-Tebit, Angela Risch, Birgit Jäger, Michael Hoffmeister, Hermann Brenner & Jenny Chang-Claude. (2006)
Effect of
NAT1
and
NAT2
Genetic Polymorphisms on Colorectal Cancer Risk Associated with Exposure to Tobacco Smoke and Meat Consumption
. Cancer Epidemiology, Biomarkers & Prevention 15:1, pages 99-107.
Crossref
Crossref
Daya SL Srivastava & Rama D Mittal. (2005) Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urology 5:1.
Crossref
Crossref
S.S. Lin, J.G. Chung, J.P. Lin, J.Y. Chuang, W.C. Chang, J.Y. Wu & Y.S. Tyan. (2005) Berberine inhibits arylamine N-acetyltransferase activity and gene expression in mouse leukemia L 1210 cells. Phytomedicine 12:5, pages 351-358.
Crossref
Crossref
Evgeniya V. Belogubova, Ekatherina Sh. Kuligina, Alexandr V. Togo, Maria B. Karpova, Julia M. Ulibina, Vladimir A. Shutkin, Kaido P. Hanson, Katrin Popowski, Igor Mosyagin, Ingolf Cascorbi, Ari Hirvonen & Evgeny N. Imyanitov. (2005) ‘Comparison of extremes’ approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. Cancer Letters 221:2, pages 177-183.
Crossref
Crossref
K. Skrętkowicz, J. Skrętkowicz, B. Gawrońska-Szklarz, W. Górnik, M. Rychlik-Sych & A. Sysa-Jędrzejowska. (2004) Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis. European Journal of Clinical Pharmacology 60:11, pages 773-778.
Crossref
Crossref
Anne C. Deitz, Nathanial Rothman, Timothy R. Rebbeck, Richard B. Hayes, Wong-Ho Chow, Wei Zheng, David W. Hein & Montserrat García-Closas. (2004)
Impact of Misclassification in Genotype-Exposure Interaction Studies: Example of
N
-Acetyltransferase 2 (
NAT2
), Smoking, and Bladder Cancer
. Cancer Epidemiology, Biomarkers & Prevention 13:9, pages 1543-1546.
Crossref
Crossref
Richard Weinshilboum & Liewei Wang. (2004) Pharmacogenomics: bench to bedside. Nature Reviews Drug Discovery 3:9, pages 739-748.
Crossref
Crossref
Rama D. Mittal, Daya S.L. Srivastava & Anil Mandhani. (2004) NAT2 gene polymorphism in bladder cancer: a study from North India. International braz j urol 30:4, pages 279-285.
Crossref
Crossref
Luisa Airoldi, Cinzia Magagnotti, Roberta Pastorelli & Roberto Fanelli. (2004) Enzyme polymorphisms influencing the metabolism of heterocyclic aromatic amines. Journal of Chromatography B 802:1, pages 175-181.
Crossref
Crossref
Cinzia Magagnotti, Roberta Pastorelli, Simonetta Pozzi, Bruno Andreoni, Roberto Fanelli & Luisa Airoldi. (2003)
Genetic polymorphisms and modulation of 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐
b
]pyridine (PhIP)‐DNA adducts in human lymphocytes
. International Journal of Cancer 107:6, pages 878-884.
Crossref
Crossref
Fatima Vrtic, Walter E. Haefeli, Jürgen Drewe, Stephan Krähenbühl & Markus Wenk. (2003) Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug. British Journal of Clinical Pharmacology 55:2, pages 191-198.
Crossref
Crossref
Petra Zschieschang, Falk Hiepe, Erika Gromnica-Ihle, Ivar Roots & Ingolf Cascorbi. (2002) Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosus. Pharmacogenetics 12:7, pages 559-563.
Crossref
Crossref
Loı̈c Le Marchand, Jean H Hankin, Lisa M Pierce, Rashmi Sinha, Pratibha V Nerurkar, Adrian A Franke, Lynne R Wilkens, Laurence N Kolonel, Timothy Donlon, Ann Seifried, Laurie J Custer, Annette Lum-Jones & Wendy Chang. (2002) Well-done red meat, metabolic phenotypes and colorectal cancer in Hawaii. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 506-507, pages 205-214.
Crossref
Crossref
Peter Meisel. (2002) Arylamine N-acetyltransferases and drug response. Pharmacogenomics 3:3, pages 349-366.
Crossref
Crossref
Alexandre Loktionov, William Moore, Steven P. Spencer, Hester Vorster, Theo Nell, Ian K. O’Neill, Sheila A. Bingham & John H. Cummings. (2002) Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detection and Prevention 26:1, pages 15-22.
Crossref
Crossref
P Wong, K Banerjee, J Massengill, S Nowell, N Lang & B Leyland-Jones. (2001) Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping. Journal of Immunological Methods 251:1-2, pages 1-9.
Crossref
Crossref
H. Wikman, S. Thiel, B. J??ger, P. Schmezer, B. Spiegelhalder, L. Edler, H. Dienemann, K. Kayser, V. Schulz, P. Drings, H. Bartsch & A. Risch. (2001) Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 11:2, pages 157-168.
Crossref
Crossref
Peter Meisel, Dorit Arndt, Eberhard Scheuch, Klaus-J??rgen Klebingat & Werner Siegmund. (2001) Prediction of Metabolic Activity From Genotype: The Gene???Dose Effect of N-Acetyltransferase. Therapeutic Drug Monitoring 23:1, pages 9-14.
Crossref
Crossref
Mehmet Simsek, Musbah O.M Tanira, Khalid A Al-Baloushi, Hameeda S Al-Barwani, Khulood M Lawatia & Riad A.L Bayoumi. (2000) Improved detection of the T341C polymorphism in human N-acetyltransferase (NAT2) gene by using two complementary PCR-RFLP methods: better than automated DNA sequencing for detection of heterozygotes. Clinical Biochemistry 33:7, pages 585-588.
Crossref
Crossref
Christian Meisel, Ivar Roots, Ingolf Cascorbi, Ulrich Brinkmann & Jürgen Brockmöller. (2000) How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport. cclm 38:9, pages 869-876.
Crossref
Crossref
Tiziana Martone, Paolo Vineis, Christian Malaveille & Benedetto Terracini. (2000) Impact of polymorphisms in xeno(endo)biotic metabolism on pattern and frequency of p53 mutations in bladder cancer. Mutation Research/Reviews in Mutation Research 462:2-3, pages 303-309.
Crossref
Crossref
William M. O'Neil, Robert K. Drobitch, Rodger D. MacArthur, Marti J. Farrough, Mark A. Doll, Adrian J. Fretland, David W. Hein, Lawrence R. Crane & Craig K. Svensson. (2000) Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 10:2, pages 171-182.
Crossref
Crossref
Jürgen Brockmöller, Ingolf Cascorbi, Stefan Henning, Christian Meisel & Ivar Roots. (2000) Molecular Genetics of Cancer Susceptibility. Pharmacology 61:3, pages 212-227.
Crossref
Crossref
Ralph I. Freudenthal, Ellen Stephens & Daniel P. Anderson. (2016) Determining the Potential of Aromatic Amines to Induce Cancer of the Urinary Bladder. International Journal of Toxicology 18:5, pages 353-359.
Crossref
Crossref